JON WIGGINTON Member, Board of Directors Dr. Wigginton is a physician and scientist with expertise in oncology drug development. He has over 25 years of experience in clinical oncology, with leadership experience in both academia and industry. Dr. Wigginton currently...
GANG YIN, Ph.D. Vice President, Platform and Process Sciences Dr. Gang Yin is an accomplished scientist and experienced R&D team leader with over 18 years of expertise in research and drug development. After earning his Ph.D. from Tsinghua University, he started...
CARLOS LUGO-PONCE Senior Vice President, QualityCarlos Lugo has over 30 years of combined experience in Quality, Compliance, Regulatory Affairs, Validation and Manufacturing, and has been the Head of Quality for Sutro since 2016. Prior to joining Sutro, Carlos held...
- Updated luvelta data from Compassionate Use Access demonstrating anti-leukemic activity in pediatric patients with relapsed/refractory CBF2AT3-GLIS2 AML to be presented in a poster at ASH 2023 - - Luvelta demonstrated encouraging preliminary anti-tumor activity in...
SOUTH SAN FRANCISCO, Calif., September 19, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Hans-Peter...
SOUTH SAN FRANCISCO, Calif., August 30, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive...
- Enrollment is underway for REFRaME-O1, the Phase 2/3 pivotal study of luveltamab tazevibulin, or luvelta, for patients with platinum-resistant ovarian cancer - - Sutro will present data from the Phase 1 dose expansion for luvelta for patients with endometrial...
- Sutro will receive $140 million upfront and is eligible to receive up to an additional $250 million in future milestone payments in exchange for the royalty, or revenue interest, in potential future sales of Vaxcyte’s products - - Transaction provides non-dilutive...
- Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, in ovarian cancer, demonstrating that FolRα-selected patients, who represent 80% of the patient...
SOUTH SAN FRANCISCO, Calif., May 31, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), todayannounced that Bill Newell, Chief Executive...
